Justices Told $200M Merck IP Award Should Be Reinstated
Biotech firm Celgene on Wednesday urged the U.S. Supreme Court to reverse a Federal Circuit decision wiping out a $200 million infringement verdict Merck won against Gilead after it was discovered...To view the full article, register now.
Already a subscriber? Click here to view full article